<!DOCTYPE html><html><head><meta charSet="utf-8" class="next-head"/><title class="next-head">ALiEM Cards</title><meta name="viewport" content="initial-scale=1.0, width=device-width" class="next-head"/><meta charset="utf-8" class="next-head"/><meta http-equiv="x-ua-compatible" content="ie=edge" class="next-head"/><link rel="apple-touch-icon" sizes="180x180" href="/static/Favicons/apple-touch-icon.png" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-32x32.png" sizes="32x32" class="next-head"/><link rel="icon" type="image/png" href="/static/Favicons/favicon-16x16.png" sizes="16x16" class="next-head"/><link rel="mask-icon" href="/static/Favicons/safari-pinned-tab.svg" color="#00b092" class="next-head"/><link rel="shortcut icon" href="/static/Favicons/favicon.ico" class="next-head"/><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Open+Sans" class="next-head"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js" as="script"/><link rel="preload" href="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js" as="script"/><link rel="preload" href="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" as="script"/><link rel="preload" href="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" as="script"/><link rel="preload" href="/_next/static/chunks/styles.9b76ae77785496d5351a.js" as="script"/><link rel="preload" href="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" as="script"/><link rel="stylesheet" href="/_next/static/css/commons.b3e9c004.chunk.css"/><link rel="stylesheet" href="/_next/static/css/styles.0fc85b66.chunk.css"/></head><body><div id="__next"><div data-reactroot=""><div><div class="header" role="banner"><div class="header__logo"><a href="/"><img src="/static/logo.svg"/></a></div><div class="header__nav-button"><button class="hamburger hamburger__squeeze"><span class="hamburger__box"><span class="hamburger__inner"></span></span></button></div><nav class="header__nav header__nav--closed" role="navigation"><ul><li><a href="/cards/">Cards</a></li><li><a href="/categories/">Categories</a></li><li><a href="/about/">About</a></li></ul></nav></div><div class="search"><div class="search__input" role="search"><input type="text" placeholder="Search" aria-label="Search for cards" value=""/></div></div></div><main class="content container" role="main"><article role="article"><h1>Supratherapeutic INR</h1><div class="card"><div class="card__meta"><div><strong>Author: </strong>Michelle Lin, MD</div><div><strong>Updated:</strong> <!-- -->8/10/2012</div></div><div class="card__content"><h1 id="overanticoagulation-and-supratherapeutic-inr-from-warfarin">Overanticoagulation and Supratherapeutic INR from Warfarin</h1>
<p><strong>ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)</strong></p>
<table>
<thead>
<tr>
<th align="right">INR</th>
<th>Therapeutic Intervention</th>
</tr>
</thead>
<tbody><tr>
<td align="right">&le;10</td>
<td><strong><em>If no bleeding:</em></strong> Hold <span class="drug">coumadin</span>. Restart when INR is therapeutic</td>
</tr>
<tr>
<td align="right">&gt;10</td>
<td><strong><em>If no bleeding:</em></strong> Hold <span class="drug">coumadin</span>. Give oral <span class="drug">vitamin K</span> (2.5 mg)</td>
</tr>
<tr>
<td align="right">Major bleed</td>
<td>Hold <span class="drug">coumadin</span>. Give <span class="drug">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class="drug">PCC</span> (<span class="drug">FFP</span> not of added benefit with 4-factor <span class="drug">PCC</span>)</td>
</tr>
</tbody></table>
<p><strong>Higher bleeding risk associated with coumadin</strong></p>
<ul>
<li>NSAIDS: non-selective and COX-2 selective</li>
<li>Antiplatelet agents: <span class="drug">aspirin</span>, <span class="drug">clopidogrel</span></li>
<li><span class="drug">Clotrimoxazole</span></li>
<li>Antibiotics (especially <span class="drug">fluoroquinolones</span>)</li>
</ul>
<p><strong>Pearl</strong></p>
<ul>
<li>Risk of intracranial hemorrhage doubles for every 1-point increase in INR</li>
</ul>
<h2 id="causes-for-supratherapeutic-inr-6">Causes for supratherapeutic INR &gt;6</h2>
<p><a href="https://www.ncbi.nlm.nih.gov/pubmed/9496982">Hylek et al. JAMA 1998 study</a></p>
<ul>
<li>Retrospective case-control study of patients with INR &gt;6</li>
<li>Enrolled 93 cases, 196 controls</li>
</ul>
<table>
<colgroup>
<col width="50%" />
<col width="50%" />
</colgroup>
<thead>
<tr class="header">
<th><strong>Risk Factor / Explanation</strong></th>
<th><strong>Odds Ratio</strong></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td>Advanced malignancy</td>
<td>16.4</td>
</tr>
<tr class="even">
<td><strong></strong>
<p><span class="drug">Acetaminophen intake</span><br/> • 4.5-9.1 g/wk<br />
• &gt; 9.1 g/wk</p></td>
<td>6.8<br />
10<br /></td>
</tr>
<tr class="odd">
<td>New medication</td>
<td>8.5</td>
</tr>
<tr class="even">
<td>Excess <span class="drug">coumadin</span> intake</td>
<td>8.1</td>
</tr>
<tr class="odd">
<td>Decreased oral intake</td>
<td>3.6</td>
</tr>
<tr class="even">
<td>Acute diarrheal illness</td>
<td>3.5</td>
</tr>
<tr class="odd">
<td>Vitamin K intake</td>
<td>0.7</td>
</tr>
<tr class="even">
<td>Alcohol use<br />
(1 drink QOD-2 drinks daily)</td>
<td>0.2</td>
</tr>
</tbody>
</table>

<h2 id="references">References</h2>
<ul>
<li>Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62 [<a href="https://www.ncbi.nlm.nih.gov/pubmed/9496982">PubMed</a>]</li>
<li>Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295. [<a href="https://www.ncbi.nlm.nih.gov/pubmed/22315259">PubMed</a>]</li>
</ul>
</div></div></article></main><div class="footer" role="contentinfo"><div class="container"><div class="row footer__cc"><div class="footer__cc-image"><a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/"><img alt="creative-commons" src="/static/by-nc-nd.svg"/></a></div><div class="footer__cc-text">This work is licensed under a<!-- --> <a rel="license" href="http://creativecommons.org/licenses/by-nc-nd/3.0/">Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License</a>.</div></div><div class="row footer__links"><div><a href="/contact/">Contact</a></div><div><a href="/contact/">Get Involved</a></div><div><a href="/about/">About</a></div></div><div class="row row--centered"><div class="container footer__disclaimer">ALiEM Cards content is intended for use by healthcare professionals. Users of this site should exercise their own clinical judgment as to the reliability and accuracy of its information. Non-healthcare-professionals who use this site do so at their own risk. Content on this site should not be construed as medical advice. Users should always confer with medical profoessionals regarding decisions about medications, evaluations and other medical treatments.</div></div></div></div></div></div><script>__NEXT_DATA__ = {"props":{"pageProps":{"card":{"slug":"supratherapeutic-INR","title":"Supratherapeutic INR","authors":["Michelle Lin, MD"],"categories":[{"slug":"hematology-and-oncology","name":"Hematology and Oncology"}],"created":"2012/08/10","updated":null,"body":"\n# Overanticoagulation and Supratherapeutic INR from Warfarin\n\n**ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)**\n\n|         INR | Therapeutic Intervention                                                                                                                                                                                                                      |\n| ----------: | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n|      \u0026le;10 | **_If no bleeding:_** Hold \u003cspan class=\"drug\"\u003ecoumadin\u003c/span\u003e. Restart when INR is therapeutic                                                                                                                                                |\n|      \u0026gt;10 | **_If no bleeding:_** Hold \u003cspan class=\"drug\"\u003ecoumadin\u003c/span\u003e. Give oral \u003cspan class=\"drug\"\u003evitamin K\u003c/span\u003e (2.5 mg)                                                                                                                         |\n| Major bleed | Hold \u003cspan class=\"drug\"\u003ecoumadin\u003c/span\u003e. Give \u003cspan class=\"drug\"\u003evitamin K\u003c/span\u003e (5-10 mg slow IVP), 4-factor \u003cspan class=\"drug\"\u003ePCC\u003c/span\u003e (\u003cspan class=\"drug\"\u003eFFP\u003c/span\u003e not of added benefit with 4-factor \u003cspan class=\"drug\"\u003ePCC\u003c/span\u003e) |\n\n**Higher bleeding risk associated with coumadin**\n\n- NSAIDS: non-selective and COX-2 selective\n- Antiplatelet agents: \u003cspan class=\"drug\"\u003easpirin\u003c/span\u003e, \u003cspan class=\"drug\"\u003eclopidogrel\u003c/span\u003e\n- \u003cspan class=\"drug\"\u003eClotrimoxazole\u003c/span\u003e\n- Antibiotics (especially \u003cspan class=\"drug\"\u003efluoroquinolones\u003c/span\u003e)\n\n**Pearl**\n\n- Risk of intracranial hemorrhage doubles for every 1-point increase in INR\n\n## Causes for supratherapeutic INR \u003e6\n\n[Hylek et al. JAMA 1998 study](https://www.ncbi.nlm.nih.gov/pubmed/9496982)\n\n- Retrospective case-control study of patients with INR \u003e6\n- Enrolled 93 cases, 196 controls\n\n\u003ctable\u003e\n\u003ccolgroup\u003e\n\u003ccol width=\"50%\" /\u003e\n\u003ccol width=\"50%\" /\u003e\n\u003c/colgroup\u003e\n\u003cthead\u003e\n\u003ctr class=\"header\"\u003e\n\u003cth\u003e\u003cstrong\u003eRisk Factor / Explanation\u003c/strong\u003e\u003c/th\u003e\n\u003cth\u003e\u003cstrong\u003eOdds Ratio\u003c/strong\u003e\u003c/th\u003e\n\u003c/tr\u003e\n\u003c/thead\u003e\n\u003ctbody\u003e\n\u003ctr class=\"odd\"\u003e\n\u003ctd\u003eAdvanced malignancy\u003c/td\u003e\n\u003ctd\u003e16.4\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"even\"\u003e\n\u003ctd\u003e\u003cstrong\u003e\u003c/strong\u003e\n\u003cp\u003e\u003cspan class=\"drug\"\u003eAcetaminophen intake\u003c/span\u003e\u003cbr/\u003e • 4.5-9.1 g/wk\u003cbr /\u003e\n• \u0026gt; 9.1 g/wk\u003c/p\u003e\u003c/td\u003e\n\u003ctd\u003e6.8\u003cbr /\u003e\n10\u003cbr /\u003e\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"odd\"\u003e\n\u003ctd\u003eNew medication\u003c/td\u003e\n\u003ctd\u003e8.5\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"even\"\u003e\n\u003ctd\u003eExcess \u003cspan class=\"drug\"\u003ecoumadin\u003c/span\u003e intake\u003c/td\u003e\n\u003ctd\u003e8.1\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"odd\"\u003e\n\u003ctd\u003eDecreased oral intake\u003c/td\u003e\n\u003ctd\u003e3.6\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"even\"\u003e\n\u003ctd\u003eAcute diarrheal illness\u003c/td\u003e\n\u003ctd\u003e3.5\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"odd\"\u003e\n\u003ctd\u003eVitamin K intake\u003c/td\u003e\n\u003ctd\u003e0.7\u003c/td\u003e\n\u003c/tr\u003e\n\u003ctr class=\"even\"\u003e\n\u003ctd\u003eAlcohol use\u003cbr /\u003e\n(1 drink QOD-2 drinks daily)\u003c/td\u003e\n\u003ctd\u003e0.2\u003c/td\u003e\n\u003c/tr\u003e\n\u003c/tbody\u003e\n\u003c/table\u003e\n\n## References\n\n- Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9496982)]\n- Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22315259)]\n"}}},"page":"/card","pathname":"/card","query":{"slug":"supratherapeutic-INR"},"buildId":"1~ee3OFOv6kXxZUoU_eCb","nextExport":true};__NEXT_LOADED_PAGES__=[];__NEXT_REGISTER_PAGE=function(r,f){__NEXT_LOADED_PAGES__.push([r, f])}</script><script async="" id="__NEXT_PAGE__/card" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/card.js"></script><script async="" id="__NEXT_PAGE__/_app" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_app.js"></script><script async="" id="__NEXT_PAGE__/_error" src="/_next/static/1~ee3OFOv6kXxZUoU_eCb/pages/_error.js"></script><script src="/_next/static/runtime/webpack-89179faa512dd01fbb62.js" async=""></script><script src="/_next/static/chunks/commons.ce4c8f8c27f9b1d9e256.js" async=""></script><script src="/_next/static/chunks/styles.9b76ae77785496d5351a.js" async=""></script><script src="/_next/static/runtime/main-cfdfd101abde4b1d3f2a.js" async=""></script></body></html>